Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
出版年份 2022 全文链接
标题
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
作者
关键词
-
出版物
Open Forum Infectious Diseases
Volume 9, Issue 8, Pages -
出版商
Oxford University Press (OUP)
发表日期
2022-07-27
DOI
10.1093/ofid/ofac343
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
- (2022) Chansavath Phetsouphanh et al. NATURE IMMUNOLOGY
- SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13
- (2022) Cameron B. Morrison et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis
- (2021) Ana Macedo et al. ANNALS OF EPIDEMIOLOGY
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes
- (2021) Dave J. Baker et al. Genome Medicine
- IL-33 in COVID-19: friend or foe?
- (2021) Yuejin Liang et al. Cellular & Molecular Immunology
- N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection
- (2021) Dandan Shan et al. Nature Communications
- Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
- (2021) Jennifer D. Hamilton et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
- (2021) et al. ANNALS OF INTERNAL MEDICINE
- COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
- (2021) Benjamin Ungar et al. Journal of Allergy and Clinical Immunology-In Practice
- Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies
- (2021) Bob Geng et al. Journal of Allergy and Clinical Immunology-In Practice
- COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk
- (2021) Arch G. Mainous et al. Frontiers in Medicine
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Longitudinal analyses reveal immunological misfiring in severe COVID-19
- (2020) Carolina Lucas et al. NATURE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of dupilumab in the treatment of atopic diseases
- (2019) Quinn Thibodeaux et al. Human Vaccines & Immunotherapeutics
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
- (2018) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
- (2009) Satish L. Deshmane et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started